Search results for "Peritoneal dialysis"

showing 10 items of 39 documents

Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure.

2012

Aims Continuous ambulatory peritoneal dialysis (CAPD) has been proposed as an additional therapeutic resource for patients with advanced congestive heart failure (CHF). The objective of this study was to determine the therapeutic role of CAPD, in terms of surrogate endpoints, in the management of patients with advanced CHF and renal dysfunction. A total of 57 candidates with New York Heart Association (NYHA) class III/IV CHF, renal dysfunction (glomerular filtration rate , 60 mL/min/1.73 m 2 ), persistent fluid congestion despite loop diuretic treatment, and at least two previous hospitalizations for acute heart failure (AHF) were invited to be included in the CAPD programme; however, 25 pa…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentRenal functionurologic and male genital diseasesKidneySeverity of Illness IndexPeritoneal dialysisPeritoneal Dialysis Continuous AmbulatoryInternal medicineSurveys and QuestionnairesmedicineAmbulatory CareHumanscardiovascular diseasesProspective StudiesRenal InsufficiencyProspective cohort studyHeart Failurebusiness.industrySurrogate endpointContinuous ambulatory peritoneal dialysisLoop diureticBrain natriuretic peptidemedicine.diseaseHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersGlomerular Filtration RateEuropean journal of heart failure
researchProduct

CAPD + hemoperfusion once a week in the management of children with end-stage renal disease

1983

With hemoperfusion there is a sharp decline in the solute concentration of the blood compartment, but immediately after HP the concentration of these substances rises to the original level (post-Hp rebound). It may be inferred that the result would be better and the rebound phenomenon less marked if hemoperfusion could be combined with a continuous dialysis system such as CAPD. The study was performed in 3 children of our CAPD programm. All patients were dialysed with 5 daily exchange each of one liter. The patients underwent at 2-hours hemoperfusion with a charcoal column (Gambro Adsorba 150 c) once a week. The data obtained with this form of treatment are indicative for a: significant in…

Malemedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyBiomedical EngineeringUrologyMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologyEnd stage renal diseasePeritoneal dialysisBiomaterials03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryHumansMedicinePlatelet activationChildIntensive care medicineDialysisCreatininebusiness.industryLiterGeneral MedicineHemoperfusionUric AcidHemoperfusionchemistryCreatinineKidney Failure ChronicUric acidFemalebusinessPeritoneal Dialysis
researchProduct

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

2011

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing tha…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyPharmaceutical SciencePeritonitisPeritonitisCeftazidimePeritoneal dialysisPharmacokineticsPeritoneal Dialysis Continuous AmbulatoryVancomycinmedicineHumansDialysisAntibacterial agentAgedbusiness.industryContinuous ambulatory peritoneal dialysisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsAmbulatoryVancomycinFemalebusinessInjections Intraperitonealmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (C…

2019

Background and aims Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r +/- DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015. Material and methods Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and toler…

Malemedicine.medical_treatmentHIV InfectionsHepacivirus0302 clinical medicine:Infections::Virus Diseases::Hepatitis Viral Human::Hepatitis C::Hepatitis C Chronic [DISEASES]ribavirina2-Naphthylaminemediana edad:virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES]ancianoSulfonamidesCoinfectionfarmacoterapiaLiver Diseasesvirus diseasesValineInfeccions per VIH - TractamentCirrhosisNephrology/drug therapyMedicine030211 gastroenterology & hepatologyDrug Therapy Combinationinsuficiencia renalmedicine.medical_specialty:virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES]GenotypeProlineSciencecompuestos macrocíclicosSurgical and Invasive Medical ProceduresGastroenterology and HepatologyAntiviral AgentsMicrobiologyUrinary System ProceduresPeritoneal dialysis03 medical and health sciencesDrug TherapyHumansLost to follow-upRenal Insufficiency ChronicUracilAgedRetrospective StudiesFlavivirusesanilidasOrganismsOrgan Transplantationmedicine.diseasedigestive system diseasesRegimenchemistryHIV-1Malalties del ronyóCarbamatesgenotipoCyclopropanesRNA virusesantivíricosSustained Virologic ResponsePhysiologyhumanoschemistry.chemical_compoundChronic Kidney DiseaseMedicine and Health SciencesRenal TransplantationAnilidesRenal Insufficiency030212 general & internal medicinePathology and laboratory medicinecoinfecciónMultidisciplinaryKidney diseasesHepatitis C virus:Infections::Infections::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::Infections::Virus Diseases::HIV Infections [DISEASES]resultado del tratamientoQR:Infections::Coinfection [DISEASES]Middle AgedMedical microbiologyHepatitis CTreatment OutcomeInfectious DiseasesTolerabilityResearch DesigncarbamatosVirusesFemaleHemodialysisPathogensVIH-1Research ArticleGlomerular Filtration RateMacrocyclic CompoundsClinical Research DesignLactams MacrocyclicResearch and Analysis MethodssulfonamidasRenal DialysisInternal medicineRibavirinMedical DialysismedicineDialysisTransplantationRenal Physiology/tratamiento farmacológicoRitonavirBiology and life sciencesbusiness.industryRibavirinestudios retrospectivosViral pathogensHepatitis C ChronicHepatitis virusesMicrobial pathogens:enfermedades parasitarias::coinfección [ENFERMEDADES]Spaindiálisis renalCo-InfectionsPhysical therapyinfecciones por VIHAdverse EventsbusinessHepatitis C - TractamenturaciloKidney diseasePLoS ONE
researchProduct

Autosomal recessive polycystic kidney disease: case report of a newborn with rare PKHD1 mutation, rapid renal enlargement and early fatal outcome

2020

Abstract Introduction Autosomal recessive polycystic kidney disease (ARPKD; MIM#263200) is one of the most frequent pediatric renal cystic diseases, with an incidence of 1:20,000. It is caused by mutations of the PKHD1 gene, on chromosome 6p12. The clinical spectrum is highly variable, ranging from late-onset milder forms to severe perinatal manifestations. The management of newborns with severe pulmonary insufficiency is challenging, and causes of early death are sepsis or respiratory failure. In cases of massive renal enlargement, early bilateral nephrectomy and peritoneal dialysis may reduce infant mortality. However, there is no conclusive data on the role of surgery, and decision-makin…

Pediatricsmedicine.medical_specialtyGenotype-phenotype correlationGenotypemedicine.medical_treatmentARPKDPulmonary insufficiencyReceptors Cell SurfaceCase ReportPeritoneal dialysisSepsis03 medical and health sciencesLiver diseaseConsanguinity0302 clinical medicineFatal OutcomeNext generation sequencingmedicineHumansGenetic Predisposition to DiseaseEthicPotter sequencePolycystic Kidney Autosomal RecessiveEthicsbusiness.industrylcsh:RJ1-570Infant Newbornlcsh:Pediatricsmedicine.diseaseAutosomal Recessive Polycystic Kidney DiseaseRespiratory failure030220 oncology & carcinogenesisMutationFemalebusiness030217 neurology & neurosurgeryInfant PrematureBilateral NephrectomyPotter sequence
researchProduct

Chemical transformations of glucose in solutions for peritoneal dialysis after sterilization and during storage

2018

The objective of this work was to estimate glucose degradation products (GDPs) in solutions for peritoneal dialysis (PD) including glucose and sodium lactate based on the change of pH and absorption of ultraviolet (UV) light. Spectrophotometric and pH-metric methods were used to measure glucose degradation and transformation of GDPs in laboratory-made solutions after heat sterilization and during storage. Mechanism of transformations of GDPs in the sterilized solutions for PD during storage and spectral characteristic of 5-HMF were studied. Common features for all the batches of the tested solutions for PD after heat sterilization were a reduce in pH, increase in the absorbance in the range…

Pharmacology5-hydroxymethylfurfuralmedicine.medical_specialtybusiness.industry3medicine.medical_treatmentPharmaceutical ScienceSterilization (microbiology)4-dideoxyglucosone-3-eneSurgeryPeritoneal dialysisperitoneal dialysismedicinebusinessActa Poloniae Pharmaceutica
researchProduct

Monitorización de la vacomicina en administración intraperitoneal en pacientes sometidos a diálisis peritoneal continua ambulatoria

2012

Objective: To validate a pharmacokinetic model of the treatments with intraperitoneal vancomycin applied to patients on continuous ambulatory peritoneal dialysis with bacterial peritonitis. Methods: To carry out a prospective study divided in 2 cohorts: the first one including ten patients of 56 ± 14 years and 65 ± 5 kg, and the second one with 10 patients (12 episodes of peritonitis) aged 52 ± 13 years and 64 ± 8 kg. The treatment consists of administering and retaining for 6 h in the peritoneal cavity a solution containing 2 g of vancomycin and 1 g of ceftazidime into 2 l of ‘‘dialysis solution’’. After the antibiotic administration, blood samples were obtained at 4, 6, 8, 10, 24, 48 and …

Pharmacologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentContinuous ambulatory peritoneal dialysisUrologyPeritonitismedicine.diseasePeritoneal dialysisPharmacokineticsCohortmedicineVancomycinProspective cohort studybusinessmedicine.drugCohort studyFarmacia Hospitalaria
researchProduct

Approach of the State Pharmacopeia of Ukraine to analytical procedures validation on the example of chloride ions assay in peritoneal dialysis soluti…

2019

The objective of this study was to develop and validate an alternative analytical procedure for the total chloride assay in solutions for peritoneal dialysis (PD). The proposed analytical procedure was validated according to the requirements of the International Conference on Harmonization (ICH) Guideline: Topic ICH Q2(R1) and the approach of the State Pharmacopeia of Ukraine (SPU). The analytical procedure was specific. The li-nearity of the procedure was evaluated in the concentration range of 76 to 114 mmol/L of chloride ions (80-120% of the stated content (95 mmol/L)) with the regression equation y = 1.0029 ∑ X -0.2269 and a correlation coefficient of 0.9989. The y-intercept of the regr…

Pharmacologyvalidationsolutions for peritoneal dialysisChromatographybusiness.industryPharmaceutical Sciencechlorides assayChlorideIonargentometric methodmedicineAnalytical proceduresPeritoneal dialysis solutionsbusinessuncertaintymedicine.drugActa Poloniae Pharmaceutica
researchProduct

Association between oral findings and laboratory tests in children and adolescents undergoing dialysis: A cross- sectional study

2017

Background Diagnosis of oral complications in the dialysis patients is important to prevent potential infections. The aim of this cross-sectional study was to compare oral findings in dialysis patients with healthy individuals and determination of the correlation of these findings and laboratory tests. Material and methods In this cross-sectional study, DMFT, dmft, DI , CI , OHIS , PI, GI and enamel defects were evaluated in 25 hemodialysis patients, 30 peritoneal dialysis patients and 26 healthy individuals. Then the correlation of laboratory tests (including Hemoglobin, Urea, Creatinine, Ca, Na, Ph, K and ALP) and oral findings was determined in each groups using SPSS (Version 16). Data a…

medicine.medical_specialtyCross-sectional studymedicine.medical_treatmentPeritoneal dialysis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine030212 general & internal medicineGeneral DentistryDialysisCreatininebusiness.industryResearchAnova test030206 dentistry:CIENCIAS MÉDICAS [UNESCO]stomatognathic diseaseschemistryOral problemsUNESCO::CIENCIAS MÉDICASOdontostomatology for the Disabled or Special PatientsHemoglobinHemodialysisbusinessJournal of Clinical and Experimental Dentistry
researchProduct

Chronic kidney disease and dialysis therapy: incidence and prevalence in the world

2021

Сhronic kidney disease (CKD) is the important public and medical problem in the world because of a large burden on health care systems. The prevalence of CKD and number of dialysis patients are increasing in the world. The prevalence and incidence of CKD depends on age, race, and gender of patients, region, and the presence of the CKD registry in a country. Diabetes mellitus (DM) and arterial hypertension (AH) are the most common causes of end stage renal disease (ESRD). It is projected that the number of dialysis patients will reach 5.5 million in 2030. Specific strategies and interventions should be urgently aimed at reducing in the burden of CKD by means of the prevention, detection and …

medicine.medical_specialtyDialysis Therapyhemodialysisbusiness.industryIncidence (epidemiology)030232 urology & nephrologyPharmaceutical SciencePharmacymedicine.diseaseurologic and male genital diseasesfemale genital diseases and pregnancy complicationsRS1-44103 medical and health sciences0302 clinical medicinePharmacy and materia medicaperitoneal dialysisInternal medicinemedicinePharmacology (medical)030212 general & internal medicinebusinesschronic kidney diseaseKidney diseaseFarmatsija
researchProduct